Economic assessment of doripenem versus imipenem in the treatment of ventilator-associated pneumonia

Journal of Medical Economics

Volumn 13, Issue 1, 2010, Pages 142-147

  McGarry, Lisa J ^a   Merchant, Sanjay ^b   Nathwani, Dilip ^c   Pawar, Vivek ^a   Delong, Kelly ^a   Thompson, David ^a   Akhras, Kasem ^b   Ingham, Michael ^b   Weinstein, Milton C ^a,d  

^a i3 Global   (Canada)

^b JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^c UNIVERSITY OF DUNDEE   (United Kingdom)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Cost effectiveness; Doripenem; Economic model; Imipenem; Ventilator associated pneumonia

Indexed keywords

AMIKACIN; DORIPENEM; IMIPENEM; VANCOMYCIN;

ADULT; ARTICLE; ARTIFICIAL VENTILATION; COST OF ILLNESS; DRUG COST; HOSPITAL COST; HUMAN; INTENSIVE CARE UNIT; TREATMENT OUTCOME; VENTILATOR ASSOCIATED PNEUMONIA;

ANTI-BACTERIAL AGENTS; CARBAPENEMS; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; HOSPITALIZATION; HUMANS; IMIPENEM; INTENSIVE CARE UNITS; LENGTH OF STAY; MIDDLE AGED; MODELS, ECONOMIC; MONTE CARLO METHOD; PNEUMONIA, VENTILATOR-ASSOCIATED; PROBABILITY; RESPIRATION, ARTIFICIAL; TIME FACTORS; UNITED STATES;

EID: 77149141144     PISSN: 13696998     EISSN: None     Source Type: Journal    
DOI: 10.3111/13696991003604108     Document Type: Article

References (24)

1. Safdar N, Dezfulian C, Collard HR, Saint S. Clinical and economic consequences of ventilator-associated pneumonia: a systematic review. Crit Care Med 2005;33:2184-2193.
2. Rello J, Ollendorf DA, Oster G, et al. Epidemiology and outcomes of ventilator-associated pneumonia in a large US database. Chest 2002;122:1883-1885.
3. MacIntyre NR. Ventilator-associated pneumonia: the role of ventilator management strategies. Respir Care 2005;50:766-773.
4. Shorr AF, Susla GM, Kollef MH. Linezolid for treatment of ventilator-associated pneumonia: a cost-effective alternative to vancomycin. Crit Care Med 2004;32:137-143.
5. Kollef MH. What is ventilator-associated pneumonia and why is it important? Respir Care 2005;50:714-724.
6. Carlet J, Ben Ali A, Chalfine A. Epidemiology and control of antibiotic resistance in the intensive care unit. Curr Opin Infect Dis 2004;17:309-316.
7. Kollef MH, Fraser VJ. Antibiotic resistance in the intensive care unit. Ann Intern Med 2001;134:298-314.
8. Park D. Antimicrobial treatment of ventilator-associated pneumonia. Respir Care 2005;50:933-953.
9. American Thoracic Society; Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005;171:388-416.
10. Johnson & Johnson Pharmaceutical Research & Development, LLC (2008) Doripenem in the Treatment of Ventilator-Associated Pneumonia. ClinicalTrials.gov Identifier NCT00211016. Available at: http://clinicaltrials. gov/ct2/show/NCT00211016.
11. Chastre J, Wunderink R, Prokocimer P, et al. Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: a multicenter, randomized study. Crit Care Med 2008;36:1089-1096.
12. Sakyo S, Tomita H, Tanimoto K, et al. Potency of carbapenems for the prevention of carbapenem-resistant mutants of Pseudomonas aeruginosa: the high potency of a new carbapenem doripenem. Jpn J Antibiotics 2006;59:220-228.
13. Merchant S, Gast C, Nathwani D, et al. Hospital resource utilization with doripenem versus imipenem in the treatment of ventilator-associated pneumonia. Clin Ther 2008;30:717-733.
14. Hjelmgren J, Berggren F, Andersson F. Health economic guidelines - similarities, differences and some implications. Value Health 2001;4:225-250.
15. Talmor D, Shapiro N, Greenberg D, et al. When is critical care medicine cost-effective? A systematic review of the cost-effectiveness literature. Crit Care Med 2006;34:2738-2747.
16. First DataBank. National Drug Data File (NDDF). Available at: http://www.firstdatabank.com/products/nddf/. Accessed February 11, 2008.
17. Paladino JA, Adelman MH, Schentag JJ, Iannini PB. Direct costs in patients hospitalised with community-acquired pneumonia after non-response to outpatient treatment with macrolide anti-bacterials in the US. Pharmacoeconomics 2007;25:677-683.
18. Dasta JF, McLaughlin TP, Mody SH, Piech CT. Daily cost of an intensive care unit day: the contribution of mechanical ventilation. Crit Care Med 2005;33:1266-1271.
19. Doubilet P, Begg CB, Weinstein MC, B, et al. Probabilistic sensitivity analysisusing Monte Carlo simulation: apractical approach. Med Decis Making 1985;5:157-177.
20. Edwards SJ, Campbell HE, Plumb JM. Cost-utility analysis comparing meropenem with imipenem plus cilastatin in the treatment of severe infections in intensive care. Eur J Health Econ 2006;7:72-78.
21. Graham E, Whalen E, Smith ME. Comparison of costs between ciprofloxacin and imipenem for the treatment of severe pneumonia in hospitalized patients. Pharmacotherapy 1994; 14: 370-371.
22. Caldwell JW, Singh S, Johnson RH. Clinical and economic evaluation of subsequent infection following intravenous ciprofloxacin or imipenem therapy in hospitalized patients with severe pneumonia. J Antimicrob Chemother 1999;43(Suppl A): 129-134.
23. Norrby SR, Eriksson M, Ottosson E. Imipenem/cilastatin versus gentamicin/clindamycin: a cost effectiveness study. Scand J Infect Dis 1986;18:371-374.
24. Rodloff AC, Laubenthal HJ, Bastian A, et al. [Comparative study of the cost-/effectiveness relationship of initial therapy with imipenem/cilastatin in nosocomial pneumonia. Group study.] Anasthesiol Intensivmed Notfallmed Schmerzther 1996;31:172-180.